Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10360894 | 0.93 | HRH3 (0.31) | GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL10176085 | 0.86 | CHRNB2 (0.36) | HRH3 | |
| SCHEMBL21210559 | 0.86 | CHRNB2 (0.36) | HRH3 | |
| SCHEMBL21786928 | 0.86 | CHRNB2 (0.32) | HRH3 | |
| SCHEMBL12209130 | 0.86 | CHRNB2 (0.32) | HRH3 | |
| SCHEMBL3996073 | 0.82 | GNAI3 (0.42) | GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL25089472 | 0.80 | HRH3 (0.34) | HRH3 | |
| SCHEMBL25646849 | 0.78 | CCR5 (0.41) | HRH3 | |
| SCHEMBL24869991 | 0.78 | GNAI3 (0.34) | GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL20707906 | 0.78 | HRH3 (0.33) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023004163-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023287928-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2021226135-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-10189843-B2 | Fused pyrazole derivative having autotaxin inhibitory activity | THE UNIVERSITY OF TOKYO (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20170158704-A1 | PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20160376278-A1 | FUSED PYRAZOLE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2016-12-29 | — | — | US | disclosed |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20160002247-A1 | 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2016-01-07 | — | — | US | disclosed |
| US-8993535-B2 | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8916594-B2 | 5-membered ring heteroaromatic derivatives having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20140051862-A1 | 5-MEMBERED RING HETEROAROMATIC DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20120184505-A1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
| WO-2011028638-A1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189843-B2 | Fused pyrazole derivative having autotaxin inhibitory activity | ENPP2, PRTN3, TPX2 | GNAI3 1680/4885GNAO1 2850/4885GNAI1 1810/4885 |
| US-20160376278-A1 | FUSED PYRAZOLE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | ENPP2, PRTN3, TPX2 | GNAI3 1680/4885GNAO1 2850/4885GNAI1 1810/4885 |
| US-20170158704-A1 | PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY | ENPP2, ITPA, IMPA1 | GNAI3 2400/4885GNAO1 3399/4885GNAI1 1504/4885 |
| US-20160002247-A1 | 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | ENPP2, UACA, IAPP | GNAI3 793/4885GNAO1 2961/4885GNAI1 654/4885 |
| US-20120184505-A1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CDC25A, CDC25B | GNAI3 1970/4885GNAO1 2976/4885GNAI1 1402/4885 |
| US-20140051862-A1 | 5-MEMBERED RING HETEROAROMATIC DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | GNAI3 524/4885GNAO1 878/4885GNAI1 707/4885 |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | GNAI3 3779/4885GNAO1 3689/4885GNAI1 3539/4885 |
| US-20160257641-A1 | NOVEL ALKYLENE DERIVATIVES | ACSS2, ACACB, ADCY2 | GNAI3 4369/4885GNAO1 3582/4885GNAI1 4209/4885 |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | GNAI3 2048/4885GNAO1 1176/4885GNAI1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.